The comprehensive characterization of human leukocyte antigen (HLA) genomic sequences remains a challenging problem. Despite the significant advantages of next-generation sequencing (NGS) in the field of Immunogenetics, there has yet to be a single solution for unambiguous, accurate, simple, cost-effective, and timely genotyping necessary for all clinical applications. This report demonstrates the benefits of nanopore sequencing introduced by Oxford Nanopore Technologies (ONT) for HLA genotyping. Samples (n = 120) previously characterized at high-resolution three-field (HR-3F) for 11 loci were assessed using ONT sequencing paired to a single-plex PCR protocol (Holotype) and to two multiplex protocols OmniType (Omixon) and NGSgo®-MX6-1 (GenDx). The results demonstrate the potential of nanopore sequencing for delivering accurate HR-3F typing with a simple, rapid, and cost-effective protocol. The protocol is applicable to time-sensitive applications, such as deceased donor typings, enabling better assessments of compatibility and epitope analysis. The technology also allows significantly shorter turnaround time for multiple samples at a lower cost. Overall, the nanopore technology appears to offer a significant advancement over current next-generation sequencing platforms as a single solution for all HLA genotyping needs.

人类白细胞抗原 (HLA) 基因组序列的综合表征仍然是一个具有挑战性的问题。尽管下一代测序 (NGS) 在免疫遗传学领域具有显着优势，但对于所有临床应用所需的明确、准确、简单、经济高效和及时的基因分型，还没有一个单一的解决方案。这份报告展示了牛津纳米孔技术 (ONT) 为 HLA 基因分型引入的纳米孔测序的好处。使用与单重 PCR 协​​议 (Holotype) 和两个多重协议 OmniType (Omixon) 和 NGSgo 配对的 ONT 测序对先前以高分辨率三场 (HR-3F) 表征的 11 个基因座的样本 (n = 120) 进行评估®-MX6-1 (GenDx)。结果证明了纳米孔测序在通过简单、快速和经济高效的方案提供准确的 HR-3F 分型方面的潜力。该协议适用于对时间敏感的应用，例如已故捐赠者的分型，从而能够更好地评估兼容性和表位分析。该技术还允许以更低的成本显着缩短多个样品的周转时间。总体而言，作为满足所有 HLA 基因分型需求的单一解决方案，纳米孔技术似乎比当前的下一代测序平台提供了显着的进步。该技术还允许以更低的成本显着缩短多个样品的周转时间。总体而言，作为满足所有 HLA 基因分型需求的单一解决方案，纳米孔技术似乎比当前的下一代测序平台提供了显着的进步。该技术还允许以更低的成本显着缩短多个样品的周转时间。总体而言，作为满足所有 HLA 基因分型需求的单一解决方案，纳米孔技术似乎比当前的下一代测序平台提供了显着的进步。